Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066079 | 0.94 | CYP2D6 (0.49) | CYP2D6ALDH1A1CHRM4CHRM2HRH3 | |
| SCHEMBL20066075 | 0.91 | CYP2D6 (0.50) | CYP2D6ALDH1A1CHRM4CHRM2POLB | |
| SCHEMBL20066073 | 0.87 | CYP2D6 (0.49) | CYP2D6ALDH1A1CHRM4CHRM2HRH3 | |
| SCHEMBL23778300 | 0.86 | CYP2D6 (0.50) | CYP2D6CHRM4HRH3OPRM1OPRL1 | |
| SCHEMBL20066008 | 0.85 | CYP2D6 (0.48) | CYP2D6ALDH1A1CHRM4CHRM2HRH3 | |
| SCHEMBL24609054 | 0.82 | CYP2D6 (0.47) | CYP2D6ALDH1A1CHRM4HRH3OPRM1 | |
| SCHEMBL3278422 | 0.81 | CA12 (0.56) | ALDH1A1CHRM4HRH3OPRM1OPRD1 | |
| SCHEMBL20066029 | 0.81 | CYP2D6 (0.51) | CYP2D6ALDH1A1CHRM4HRH3POLB | |
| SCHEMBL20066030 | 0.80 | CYP2D6 (0.55) | CYP2D6ALDH1A1CHRM4OPRM1KDM4E | |
| SCHEMBL23778348 | 0.80 | CYP2D6 (0.53) | CYP2D6CHRM4HRH3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | claimed |
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | claimed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | claimed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | claimed |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-09-17 | — | — | US | claimed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | claimed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| WO-2018069732-A1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | CYP2D6 216/4885ALDH1A1 2470/4885CHRM4 3/4885 |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CYP2D6 182/4885ALDH1A1 1554/4885CHRM4 3/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885ALDH1A1 2429/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.